Welcome to our dedicated page for Apimeds Pharmaceuticals US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apimeds Pharmaceuticals US, Inc. filings document a Delaware clinical-stage biopharmaceutical issuer with common stock registered on NYSE American under APUS and emerging growth company status. Recent 8-K and 12b-25 records cover material definitive agreements, governance and executive changes, shareholder written-consent and voting matters, preferred stock and convertible-note conversion disclosures, and capital-structure matters.
The filing record also includes notices tied to delayed Form 10-K reporting and NYSE American continued-listing compliance, along with disclosures related to settlement agreements and merger-related governance matters. Periodic and event filings frame Apimeds' operating and financial results, risk factors, and clinical or regulatory disclosures for the Apitox program.
Apimeds Pharmaceuticals US, Inc. filed an amended report stating that a written Stockholder Consent delivered on March 20, 2026 is null and void. That consent had purported to remove four directors, including Elona Kogan and Dr. Bennett Weintraub, and to remove Dr. Vin Menon as CEO and Erick Frim as CFO.
The company explains that the consent used 6,416,365 shares of common stock that were subject to an irrevocable proxy granted to the company under a Stockholder Support and Lock-Up Agreement related to its merger with MindWave Innovations Inc. Because the proxy holder did not authorize their use and the consent also conflicted with waiver and anti‑frustration covenants in that agreement, the company states the consent and related bylaw amendments are of no force or effect. As a result, Apimeds plans to proceed with actions described in its Schedule 14C information statement previously mailed to stockholders.
Apimeds Pharmaceuticals US, Inc. notified the SEC that it cannot file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 on time and expects to file within the fifteen‑day grace period provided by Rule 12b-25.
The Company says it needs additional time to complete its year-end financial statements and for its independent auditor to finish the review and audit.
Apimeds Pharmaceuticals US, Inc. is implementing a 1-for-10 reverse stock split of its issued and outstanding common stock. Stockholders holding a majority of the voting power approved the action by written consent on December 1, 2025.
The company plans to file a charter amendment in Delaware on or about March 25, 2026, and has set 12:01 a.m. Eastern Time on March 26, 2026 as the effective time. Apimeds expects its common stock to begin trading on a split-adjusted basis on the NYSE American under the symbol APUS on March 26, 2026, with a new CUSIP of 03771D201.
Apimeds Pharmaceuticals US, Inc. is notifying stockholders that consenting holders holding approximately 51% approved several corporate actions on December 1, 2025, including conversions of Series A preferred and convertible notes, a proposed 1-for-10 reverse stock split (board may elect to implement or abandon), an amendment to reduce par value from $0.01 to $0.001, an increase of shares available under the 2024 Equity Incentive Plan to 2,096,679, and adoption of a 2025 Equity Incentive Plan.
The approvals were taken in connection with a merger that closed on December 1, 2025, after which MindWave became a direct wholly owned subsidiary and MindWave holders, on an as-converted, fully diluted basis, will collectively hold 90.9% of the Company’s equity. The Preferred Stock Conversion and Notes Conversion will not be effected unless NYSE American approves the Company’s new listing application. The Information Statement was first mailed on or about March 5, 2026 and the actions become effective on or about March 25, 2026 (at least twenty calendar days after mailing).
Apimeds Pharmaceuticals US, Inc. filed Amendment No. 2 to its Form 8-K to add financial disclosures related to a previously reported reverse merger. The amendment supplies unaudited consolidated financial statements as of September 30, 2025, audited statements for the years ended March 31, 2025 and 2024, and unaudited pro forma consolidated financial information required by Item 9.01. It does not report new events after the original 8-K and does not change earlier disclosures except for providing these financial exhibits.
Apimeds Pharmaceuticals US, Inc. filed Amendment No. 2 to its current report to add full financial statements and unaudited pro forma information for its reverse merger with MindWave Innovations Inc. MindWave is a digital-asset-focused business holding $132.3 million of digital assets at fair value as of September 30, 2025, mainly Bitcoin, Tether and its native NILA token.
MindWave reported net income of $55.9 million for the year ended March 31, 2025, driven by unrealized and realized gains on digital assets, and a net loss of $6.6 million for the six months ended September 30, 2025 as digital asset values moved the other way. The pro forma data treat MindWave as the accounting acquirer, with its prior shareholders holding 90.9% of Apimeds’ equity on an as-converted basis at closing, highlighting that the combined company is effectively MindWave’s public listing vehicle.